| Drug General Information |
| Drug ID |
D01TOU
|
| Former ID |
DNC012480
|
| Drug Name |
FLUANISONE
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C21H25FN2O2
|
| Canonical SMILES |
COC1=CC=CC=C1N2CCN(CC2)CCCC(=O)C3=CC=C(C=C3)F
|
| InChI |
1S/C21H25FN2O2/c1-26-21-7-3-2-5-19(21)24-15-13-23(14-16-24)12-4-6-20(25)17-8-10-18(22)11-9-17/h2-3,5,7-11H,4,6,12-16H2,1H3
|
| InChIKey |
IRYFCWPNDIUQOW-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| SuperDrug ATC ID |
N05AD09
|
| Target and Pathway |
| Target(s) |
Alpha-1A adrenergic receptor |
Target Info |
Inhibitor |
[1]
|
|---|
| Alpha-1B adrenergic receptor |
Target Info |
Inhibitor |
[1]
|
| 5-hydroxytryptamine 2A receptor |
Target Info |
Inhibitor |
[1]
|
| D(2) dopamine receptor |
Target Info |
Inhibitor |
[1]
|
| Alpha-1D adrenergic receptor |
Target Info |
Inhibitor |
[1]
|
|
KEGG Pathway
|
Calcium signaling pathway
|
|
cGMP-PKG signaling pathway
|
|
Neuroactive ligand-receptor interaction
|
|
AMPK signaling pathway
|
|
Adrenergic signaling in cardiomyocytes
|
|
Vascular smooth muscle contraction
|
|
Salivary secretionhsa04020:Calcium signaling pathway
|
|
Gap junction
|
|
Serotonergic synapse
|
|
Inflammatory mediator regulation of TRP channelshsa04015:Rap1 signaling pathway
|
|
cAMP signaling pathway
|
|
Dopaminergic synapse
|
|
Parkinson's disease
|
|
Cocaine addiction
|
|
Alcoholismhsa04020:Calcium signaling pathway
|
|
Salivary secretion
|
|
NetPath Pathway
|
IL2 Signaling PathwayNetPath_14:IL2 Signaling Pathway
|
|
PANTHER Pathway
|
Alpha adrenergic receptor signaling pathwayP00002:Alpha adrenergic receptor signaling pathwayP04374:5HT2 type receptor mediated signaling pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
|
Dopamine receptor mediated signaling pathway
|
|
Nicotine pharmacodynamics pathway
|
|
Pathway Interaction Database
|
LPA receptor mediated events
|
|
Reactome
|
Adrenoceptors
|
|
G alpha (q) signalling events
|
|
G alpha (12/13) signalling eventsR-HSA-390696:Adrenoceptors
|
|
G alpha (12/13) signalling eventsR-HSA-390666:Serotonin receptors
|
|
G alpha (q) signalling eventsR-HSA-390651:Dopamine receptors
|
|
G alpha (i) signalling eventsR-HSA-390696:Adrenoceptors
|
|
G alpha (12/13) signalling events
|
|
WikiPathways
|
Monoamine GPCRs
|
|
Calcium Regulation in the Cardiac Cell
|
|
GPCRs, Class A Rhodopsin-like
|
|
Gastrin-CREB signalling pathway via PKC and MAPK
|
|
Endothelin Pathways
|
|
GPCR ligand binding
|
|
GPCR downstream signaling
|
|
AMPK SignalingWP58:Monoamine GPCRs
|
|
Vitamin D Receptor Pathway
|
|
AMPK SignalingWP733:Serotonin Receptor 2 and STAT3 Signaling
|
|
Serotonin Receptor 2 and ELK-SRF/GATA4 signaling
|
|
SIDS Susceptibility Pathways
|
|
GPCRs, OtherWP666:Hypothetical Network for Drug Addiction
|
|
Genes and (Common) Pathways Underlying Drug Addiction
|
|
Nicotine Activity on Dopaminergic NeuronsWP58:Monoamine GPCRs
|
|
GPCRs, Other
|
| References |
| REF 1 | J Med Chem. 1987 Nov;30(11):2099-104.2-Phenylpyrroles as conformationally restricted benzamide analogues. A new class of potential antipsychotics. 1. |
|---|
